{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-030393","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.271136+00:00","generated_at":"2026-06-21T15:50:50.849031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Twist Bioscience reports FY2022 revenue $203.6M (+54% YoY); guides FY2023 revenue $261-269M","bullets":["FY2022 revenue $203.6M, up 54% YoY; net loss $217.9M ($4.04/share) vs $152.1M loss in FY2021.","Q4 FY2022 revenue $57.3M (up 51% YoY); net loss $51.1M ($0.91/share).","Full year orders $226M, up 42% YoY; shipped 558,000 genes vs 372,000 in FY2021.","FY2023 revenue guidance $261-269M; FY2024 target $350M.","Promoted Patrick Finn, Ph.D. to president and COO; partnered with Illumina and PacBio."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-030393","json":"https://secwatch.observer/filing/0001628280-22-030393.json","markdown":"https://secwatch.observer/filing/0001628280-22-030393.md","text":"https://secwatch.observer/filing/0001628280-22-030393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/0001628280-22-030393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/twist-20221118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:50:50.849031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a58f03bf1db61f9415612aede5053eeecdb4c88","claim":"Twist Bioscience Corp reported fiscal year ended September 30, 2022 results: revenue $203.6 million, net income $217.9 million, EPS $4.04 per share. Guidance initiated.","evidence_excerpt":"FISCAL 2022 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2022 were $226 million compared to $159.5 million for fiscal 2021. • Revenue : Total revenues for fiscal 2022 were $203.6 million compared to $132.3 million for fiscal 2021. • Cost of Revenues : Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021. • Research and Development Expenses : Research and development expenses for fiscal 2022 were $120.3 million compared to $69.1 million for fiscal 2021. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2022 were $212.9 million compared to $135.9 million for fiscal 2021. • Net Loss: Net loss attributable to common stockholders for fiscal 2022 was $217.9 million , or $4.04 per share, compared to $152.1 million , or $3.15 per share, for fiscal 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/0001628280-22-030393-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended September 30, 2022"},{"label":"Revenue","value":"$203.6 million"},{"label":"Net income","value":"$217.9 million"},{"label":"EPS","value":"$4.04 per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8c5b7a757ecd0e80724cdde9f2fa2fc5f5b8c589","claim":"Twist Bioscience Corp reported the fourth quarter of fiscal 2022 results: revenue $57.3 million, net income $51.1 million, EPS $0.91 per share. Guidance initiated.","evidence_excerpt":"FISCAL 2022 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2022 were $62.1 million compared to $45.2 million for the same period of fiscal 2021 . • Revenue: Total revenues for the fourth quarter of fiscal 2022 were $57.3 million compared to $38.0 million for the same period of fiscal 2021 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2022 was $31.6 million compared to $22.5 million for the same period of fiscal 2021 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2022 were $29.6 million compared to $19.4 million for the same period of fiscal 2021 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2022 were $54.2 million compared to $38.2 million for the same period of fiscal 2021 . • Net Loss: Net loss attributable to common stockholders for the fourth quarter of fiscal 2022 wa","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/0001628280-22-030393-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of fiscal 2022"},{"label":"Revenue","value":"$57.3 million"},{"label":"Net income","value":"$51.1 million"},{"label":"EPS","value":"$0.91 per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}